Results 81 to 90 of about 18,017 (247)
, 2016 Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa with Potent Anticoagulant and Antithrombotic ...
Michael R. Wiley (189278) +20 more
core +1 more source
The impact of systemic long‐term medications for the development of age‐related macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä +3 more
wiley +1 more source
Anticoagulant treatment: the end of the old agents?
Swiss Medical Weekly, 2012 New oral anticoagulants used as single target inhibitors of coagulation enzymes have been developed and tested in extensive trial programmes. Results of most of these trials showed non-inferior and/or superior efficacy and safety compared to ...
Lukas Graf, Dimitrios A Tsakiris
doaj +1 more source
Andexanet alfa for the reversal of factor Xa inhibitors.
, 2019 Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or ...
Dincq, A S +19 more
core +1 more source
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
British Journal of Pharmacology, EarlyView.Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
Betrixaban – the next direct factor Xa inhibitor?
Expert Review of Hematology, 2016 Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative ...
Thoenes, Martin +4 more
openaire +4 more sources
Design and synthesis of novel factor Xa inhibitors.
, 2000 Design and synthesis of novel factor Xa ...
Jian. Cui (7999973)
core
Oral factor Xa inhibitors in acute coronary syndromes
, 2009 Factor Xa inhibitors, a new class of oral anticoagulants, have been evaluated in the phase II ATLAS ACS-TIMI 46 and APPRAISE trials. addition of these agents to standard therapy has tended to reduce the incidence of adverse cardiovascular events at the ...
Gregory Y. H. Lip +5 more
core +1 more source
Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases
British Journal of Pharmacology, EarlyView.Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden +3 more
wiley +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2019 Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS +7 more
doaj +1 more source